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stakeholders (including researchers, industry, academia, FDA, clinicians, and payers) 
play an important role in translation. Avalere defined four stages in the translation of 
PROs: issue identification, research, clinical practice, and implementation in quality 
and performance measurement. Literature revealed that PROs for research purposes 
must be developed, tested, and evaluated with baseline science standards in mind, 
such as psychometric soundness, rigor, validity, generalizability, and aggregatabil-
ity. PROs used in clinical practice are subject to additional criteria considering the 
science behind practicality, interoperability, and timing/mode of administration. At 
the implementation stage, there is the opportunity to define a particular outcome or 
process of care that can be assessed by a PRO. Once rigorously evaluated for scien-
tific acceptability, feasibility of data collection, and other criteria, PRO measures can 
be implemented in quality reporting or payment programs with established bench-
marks. ConClusions: Stakeholders are still ironing out the “kinks” of the develop-
ment, use, and implementation of PROs. Our conceptual framework for PRO translation 
can provide a starting point for stakeholders interested in applying best practices to 
the routine use of PROs in clinical trials and at the point of care, and as PRO measures 
become more sophisticated, in quality reporting and payment programs.
PIH50
CHoosIng between tHe PromIs global and eq-5d for ComParatIve 
effeCtIveness researCH: are tHey really dIfferent?
Runge SK, Craig BM
Moffitt Cancer Center, Tampa, FL, USA
objeCtives: To inform the design of comparative effectiveness studies (CER), a 
head-to-head psychometric comparison of the PROMIS Global and EQ-5D instru-
ments is needed. Methods: In 2013, 2289 US adults completed an online survey 
including 10 items from the PROMIS Global and 5 items from the 3 EQ-5D versions 
(EQ-5D-3L, EQ-5D-Y, and EQ-5D-5L) in random order. After testing for unidimen-
sionality between each pair of these 25 items, we conducted 3 separate exploratory 
factor analyses (EFA) between the PROMIS Global and each EQ-5D version. Next, we 
performed an item-response-theory (IRT) analysis for factors shared between the 
2 instruments. Item levels with insufficient responses (n< 40) were collapsed. The 
relative degree of information obtained by each instrument was assessed using an 
unconstrained graded response model. Results: All items were positively cor-
related (0.32 to 0.98). Regardless of EQ-5D version, EFA analyses identified 3 factors 
(eigenvalue > 1): Physical Health (PH), Mental Health (MH), and Quality of Life (QL). 
Each item uniquely loaded to a single factor after rotation. Unlike PH and MH, QL 
included only PROMIS items. At a threshold of 0.5 in standard error, the IRT analy-
ses showed similar PH information function ranges by instrument (-0.2 to 2.8 for 
EQ-5D-5L vs. -0.2 to 2.4 for PROMIS Global). However, the MH information range for 
EQ-5D-5L was substantially narrower than the range for the PROMIS Global (0.3 to 
2.4 vs. -0.8 to 2.8). ConClusions: The PROMIS Global includes 5 items that extend 
the measurement of general health beyond the 2 factors shared with the EQ-5D. 
When comparing the remaining 5 items of the PROMIS Global to the EQ-5D, the 
instruments appear to share information ranges in PH, but the PROMIS Global has 
a broader MH range than the EQ-5D. These similarities and differences are impor-
tant considerations when choosing between the PROMIS Global and EQ-5D for CER.
PIH51
ImPaCt of symPtomatIC burden among women dIagnosed wItH 
uterIne fIbroIds on HealtH-related qualIty of lIfe: an assessment 
usIng uterIne fIbroId symPtom and qualIty of lIfe questIonnaIre 
(ufs-qol)
Soliman AM1, Margolis MK2, Castelli-Haley J1, Coyne KS2
1AbbVie Inc., North Chicago, IL, USA, 2Evidera, Bethesda, MD, USA
objeCtives: Uterine fibroids (UF) are associated with significant reduction in 
health-related quality of life (HRQL). This cross-sectional survey examined the 
impact of UF-related symptoms on HRQL using a disease-specific instrument, the 
UFS-QoL. Methods: An online survey of US women between 18 and 54 years was 
conducted using 3 large respondent panels as a sampling frame. Data collected 
included demographics, UF prevalence, symptoms, HRQL and health-related produc-
tivity. Descriptive statistics were used to examine the impact of symptom presence, 
symptom severity, bothersomeness, and number of UF-related symptoms on multiple 
domains of HRQL. Analyses were weighted to match the population distribution of 
age, education, region, and household income of US female population. Results: 
59,411 (15.5%) of the panel members who were contacted completed the prevalence 
screener; 5,879 met inclusion criteria for survey completion. Of those, 1,397 had UF 
and no hysterectomy. Mean age was 42.8 years; 65% were white; 62% were married 
or in a civil union. Among the most common symptoms experienced in the past 4 
weeks, at least 49% rated each symptom as at least “moderate” severity and > 87% 
rated a symptom as at least “somewhat bothersome”. Mean UFS-QoL subscale scores 
were significantly (p< 0.05) worse among women who reported each UF symptom 
versus women in whom the symptom was absent. In particular, the presence of 
bleeding and also non-bleeding symptoms (pelvic pressure, low back pain, abdominal 
pain, bloating, and fatigue/weariness/anemia) was related to worse UFS-QoL subscale 
scores. Women who rated their UF symptoms as severe had significantly (p< 0.001) 
worse UFS-QoL scores versus women with mild or moderate UF symptoms. In addi-
tion, UFS-QoL subscale scores worsened as the number of UF symptoms experienced 
increased. ConClusions: HRQL among women with UF was significantly impacted 
by UF-related symptoms. A more pronounced impact was observed as the number 
and severity of symptoms increased.
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objeCtives: A predominant Health-Related Quality of Life Model (described by 
Wilson and Cleary in 1995) proposes a sequential relationship from biological and 
physiological variables to perceived health and overall quality of life. We assessed 
the extent to which disability mediates the association between mental and physi-
cal conditions with perceived health. Methods: Data come from the WHO World 
Mental Health (WMH) Surveys carried out in 22 countries worldwide (n = 51,344 
respondents, 72.0% response rate). We assessed 9 common mental disorders with 
the WHO Composite International Diagnostic Interview v3.0 (CIDI), and 10 chronic 
physical with a checklist. Perceived health (PH) in the previous 30 days was assessed 
using a numerical scale (from 0, worst, to 100, best). Disability was assessed using 
a modified WHO Disability Assessment Schedule 2.0 (WHODAS). Path analysis and 
multigroup techniques were used to estimate total effects of physical and mental 
conditions on perceived health PH and their separate direct and indirect (through 
the latent and observed WHODAS dimensions) effects. Results: 12-month preva-
lence was 14.4% for any mental and 51.4% for any physical condition. Disability was 
common and a 31.7% had problems with Role functioning, 11.4% with Mobility and 
8.3% with Stigma. Overall mean Perceived Health (PH) scores was 81. The model 
explained 36% of PH score variance and estimated a significant score decrement 
of 8.5 for individuals with a mental disorder and of -8.2 for those with a physical 
condition. Of those decrements, 73.7% (mental) and 59.0% (physical) were “indirect” 
effects (i.e., mediated by disability). Mediation importance of disability domains dif-
fered by mental and physical conditions. ConClusions: A large proportion of the 
decrement in perceived health associated with common conditions is mediated by 
disability. Disability mediation patterns are different for mental and physical condi-
tions. These data support the validity of the Health-Related Quality of Life Model.
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HealtH related qualIty of lIfe In PatIents usIng ComPlementary 
alternatIve medICIne (HomeoPatHy) In quetta, PakIstan
ul Haq N1, Akram A1, Iqbal Q1, Naseem A1, Mohammd S1, Ahmed N1, Farooqui M2
1University of Balochistan, Quetta, Pakistan, 2Universiti Teknologi MARA (Bertam campus), 
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objeCtives: To evaluate the Health related quality of life among patients using 
complementary Alternative medicine (homeopathy) in Quetta, Pakistan. Methods: 
A cross sectional, descriptive study was undertaken among the patients visiting 
three major homeopathic clinics in Quetta City, Pakistan. Health related quality of 
life was assessed using European Quality of Life scale (EQ-5D). Descriptive analysis 
was used to elaborate patients’ demographic characteristics while inferential sta-
tistics were applied to report the association among study variables. Results: Out 
of 500 questionnaires distributed 486 were received with a response rate of 97.2%. 
Gender distribution was 264 (54.4%) males. Mean age of the study participants was 
34.05 ± 13.0 years with 334 (68.7%) married and 431 (88.7%) having urban residency. 
The mean EQ-5D descriptive score and EQ-VAS score were 0.59 ± 0.22 and 60.19 ±16.9 
respectively. ConClusions: The health related quality of life in patients using 
Homeopathy is slightly low then Health related quality of life of general population 
of Quetta. This study provides baseline assessment for the health status of patients 
using homeopathy and the results could be applied in clinical practice.
PIH55
faCtors ImPaCtIng PersonalIzed medICIne test adoPtIon: evaluatIng 
PatIent PreferenCes and wIllIngness to Pay
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1University of Washington, Seattle, WA, USA, 2Canadian Centre for Applied Research in Cancer 
Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada
objeCtives: Personalized medicine tests (PMT) are increasingly available in the 
healthcare marketplace. The diffusion of such technologies is in part a function of 
the collective preferences of patients, providers, and payers. The objective of our study 
was to identify the attributes of PMTs most important to patients and thus likely to 
impact individual decisions and population level adoption. Methods: We used a 
mixed methods study design to identify the attributes of PMTs that impact patient 
decision-making. We recruited patients with and without prior PMT experience to 
participate in focus groups and interviews via flyers, provider contacts, and disease 
support groups. Patients completed an attributes ranking exercise and a payment 
card scenario to estimate willingness-to-pay (WTP) for PMTs. Analysis of transcripts 
was performed using thematic coding, analysis of attribute ranking used a rank-
ordered logit model, and payment card data was conducted using interval regres-
sion. Results: We contacted 32 patients of which 20 ultimately participated (focus 
groups: 14; interviews: 6). Analysis of the attribute rankings indicated that the most 
important attributes were: 1) ability to select the appropriate treatment, 2) benefit to 
family members, and 3) quality of life after testing. The rankings for these character-
istics were all statistically significant. The average willingness-to-pay for a PMT was 
$1,528 (95%CI: $361-2,694). Patients making less than $25K/year had a statistically 
significant lower WTP ($373) compared to the population average. ConClusions: 
Patients showed a strong preference for the ability to select the appropriate treatment 
based on test results as well as the impact of test results on their family and their 
quality of life. Patients were willing to pay more than would typically be required 
in an insured population but less than the full cost of some commonly used PMTs. 
This work will ultimately be used to inform the development of a discrete choice 
experiment.
IndIvIdual’s HealtH – Health Care use & Policy studies
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objeCtives: Regulatory policies, including economic incentivization through pat-
ent extensions, have been implemented to stimulate pediatric research, however 
disparity exists for the neonatal subpopulation. This analysis was conducted to 
identify the availability of neonate-specific data for frequently used medications in 
Neonatal Intensive Care Units (NICUs) and to determine the extent to which pedi-
atric exclusivity has increased information for drugs used in neonates. Methods: 
A search was conducted utilizing the FDALabels database to identify all FDA-
approved NDA, BLA and ANDAs from 01/01/1980 to 08/01/2013 searching for the 
terms “neonate”, “newborn” and “infant” present in any of the following label sec-
tions; “Indication and Usage”, “Dosage and Administration” and “Pediatric Use”. 
The results were cross-referenced with a recently published list of 100 frequently 
prescribed drugs in NICUs and drugs granted pediatric exclusivity by the FDA as 
of August, 2013. Results: A total of 737 unique labels for 110 distinct drugs were 
identified (including 18 combination products and 15 modified versions of previ-
ously marketed drugs). “Newborn” was identified in 450 labels; “infant” in 414 labels 
and “neonate” in 167 labels. More than one search term was found in 294 labels. Only 
19% of drugs frequently used in NICUs mentioned neonates, newborns or infants on 
their labels. Mention of neonates, newborns or infants occurred in 4.5% (n= 9) of the 
drugs with pediatric exclusivity; while 8.7% (n= 17) of drugs granted pediatric exclu-
sivity were used frequently in the NICU. Only two drugs frequently used in NICUs 
mentioned neonate, newborn or infant on their label and had pediatric exclusiv-
ity. ConClusions: Despite regulatory incentives, a paucity of neonatal data exist 
for drugs frequently used in NICUs. Our data suggest that pediatric exclusivity did 
not yield sufficient neonatal data.
PIH57
ImPaCt of tHe PatIent ProteCtIon and affordable Care aCt 
ContraCePtIve Coverage mandate on utIlIzatIon of refIllable and 
long-aCtIng reversIble ContraCePtIves
Vlahiotis A1, Tian Y1, Iyengar R2
1Express Scripts, St. Louis, MO, USA, 2Express Scripts Holding Company, St. Louis, MO, USA
objeCtives: One provision of the Patient Protection and Affordable Care Act (PPACA) 
requires that most insurers make prescription contraceptives—including refillable 
and long-acting reversible contraceptive methods (LARCs)—available at no out-
of-pocket cost to beneficiaries. The objective of this study was to determine if the 
implementation of the mandate increased contraceptive utilization. Methods: 
We conducted a retrospective analysis using integrated pharmacy and medical 
claims for three cohorts of commercially-insured females aged 15 to 49. Each cohort 
(n= 360143, n= 352,169, and n= 391,138) was continuously enrolled for 12-month 
periods, respectively. “Pre-PPACA-Period 1” (January 1, 2011 to June 30, 2011) con-
sidered cost and utilization two years prior to PPACA. “Pre-PPACA-Period 2” (January 
1, 2012 to June 30, 2012) looked at the year prior to PPACA implementation, and the 
“Post-PPACA Period” (January 1, 2013 to June 30, 2013) captured the early experience 
immediately after implementation of the coverage mandate. Two pre-PPACA-periods 
allowed for better understanding of underlying secular trends occurring prior to 
the mandate. The incidence of new refillable and LARC methods, discontinuation 
and switching patterns and cost were measured across each time period. Results: 
The incidence of refillable contraceptive use increased minimally: from 3.45% in 
the first half of 2011 to 3.59% in the first half of 2012, and to 3.72% in the first half 
of 2013. The incidence of LARC use increased substantially (44.4% from 0.50% to 
0.65% between the first half of 2011 and the first half of 2013). The initiation rate 
of LARCs was significantly higher after the mandate compared to previous periods 
(OR= 1.45, 95% CI = 1.36-1.54), possibly due to increased switching from refillable to 
LARC methods. ConClusions: We found little evidence that the PPACA contracep-
tive coverage mandate rule has yet resulted in meaningful increases in refillable 
contraceptive use, but it was associated with an increase in the initiation of LARCs.
PIH58
tHe ratIonale of early PresCrIPtIon of antIbIotICs In 
organoPHosPHorus PoIsonIng PatIents
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objeCtives: To study the rationale of early prescription of antibiotics in case of 
patients with Organophosphorus poisoning. Methods: In this study patients 
admitted to the ICU due to organophosphorus poisoning during a six-month 
period were included. Patients were grouped into group-A and group-B on the 
basis of antibiotics prescribed and not prescribed respectively.  The prescription of 
antibiotics was classified as prophylactic, empirical and definitive depending on 
the time of prescription. The effect of antibiotic prescription on the length of stay, 
cost and clinical outcome was observed. The cost of treatment was obtained from 
the finance department of the hospital. The length of stay and cost of treatment 
for the two groups were compared using the non-parametric Mann-Whitney U 
test. Results: There were 54 patients categorized in three groups according to the 
severity of poisoning as mild (22%), moderate (48%) and severe (30%). Antibiotics 
were prescribed for 74.07% of the patients. Prophylactic antibiotics were prescribed 
in 53.7% cases. The median cost of treatment for group-A patients was INR 60,216 
and for group-B patients was INR 27,225 (p= 0.001). The median length of stay 
for group-A and group-B was 14 days and 10 days respectively (p= 0.011). The 
median cost of treatment for moderately poisoned patients prescribed with pro-
phylactic antibiotics was INR 74595.6 as compared to INR 30,902 for moderately 
poisoned patients of group-B (p< 0.05). ConClusions: Early prescription of anti-
biotics without any evidence of infection in case of organophosphorus poisoning 
patients showed a higher cost of treatment and inferior outcomes as compared 
to OPP cases where a prophylactic antibiotic was not prescribed. The use of higher 
antibiotics in these cases also lead to increase in antibiotic resistance. There is a 
need to revise the antibiotic prescription guidelines in case of Organophosphorus 
poisoning patients.
PIH59
PrevalenCe and determInants of use of PotentIally InaPProPrIate 
medICatIons In elderly InPatIents: stoP and start CrIterIa
Boya C, Goud T, Spurthy R, Kathhon R, Ravindra R
CES college of pharmacy, kurnool, India
objeCtives: Use of potentially inappropriate medications (PIMs) among the elderly 
is a serious public health problem because it is intrinsically linked to increased 
morbidity and mortality, causing the high costs to public health systems. Objectives 
of this study were to determine the prevalence and predictors of PIM prescribing 
in elderly inpatients using STOP and START criteria Methods: The prospective 
observational study was carried at a private tertiary care hospital. Prescriptions 
of elderly inpatients aged 60 years and above were collected and analyzed. PIMs 
were identified with the help of STOP and START criteria. Predictors associated 
with use of PIMs were identified by bivariate and multivariate logistic regression 
analysis. Results: The results were based on data of 60 patients. More than half 
(56%) were males and 50% were aged between 60–69 years with a mean average 
age of 69 years. Mean number of diagnoses and medications were two and nine, 
respectively. A total of 18 (30%) patients were prescribed with at least 1 PIM according 
STOP Criteria. Most commonly prescribed PIMs were systemic corticosteroids (29%) 
followed by theophyline (18%) and betablockers (10%). On multivariate regression, 
important predictors for PIM prescribing were found to polypharmacy, number of 
diagnoses. ConClusions: The results show that PIMs prescribing is high in Indian 
elderly inpatients STOP and START criteria, it is more effective in identifying the 
PIMs. This study is ongoing and we will present the data upto 250 patents before 
the presentation.
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evaluatIng fraCture-related exPenses and HealtH Care resourCe 
utIlIzatIon among Post-menoPausal women In tHe u.s. medICaId 
PoPulatIon
Xie L1, Keshishian A1, Wang Y1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, The University of Michigan, 
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objeCtives: To evaluate fracture-related expenses and health care resource utiliza-
tion among post-menopausal women in the U.S. Medicaid population. Methods: 
Female patients diagnosed with fractures (International Classification of Disease, 
9th Revision, Clinical Modification [ICD-9-CM] codes: 733.12-.16, 805.0, 805.2, 805.4, 
805.6, 805.8, 808.0, 808.4, 808.8, 810.0, 812.0, 812.2, 812.4, 813.0, 813.2, 813.4, 813.8, 
814.0, 820.0, 820.2, 820.8, 821.0, 821.2, 823.0, 823.2, 823.4, 823.8) were identified using 
U.S. Medicaid data from 01JAN2009 through 31DEC2009. The initial diagnosis date 
was designated as the index date. A control cohort that included patients without 
fractures of the same age, race, region and baseline Charlson Comorbidity Index 
score was created. The index date for the control cohort was randomly assigned to 
minimize selection bias. Patients in both cohorts were required to be age ≥ 50 years, 
with continuous medical and pharmacy benefits for 1-year pre- and post-index date. 
Propensity score matching (PSM) was used to compare health care costs and utiliza-
tions during the follow-up period. Results: Before matching (n= 80,516), fracture 
patients were more likely to be white (71.2% vs. 46.2%), reside in the South U.S. region 
(39.2% vs. 34.1%) and have chronic obstructive pulmonary disease (26.7% vs. 21.3%). 
After 1:1 PSM, a total of 22,089 patients with proportionate baseline characteristics 
were matched from each cohort. Patients in the fracture cohort had higher propor-
tions of inpatient stays (31.0% vs. 8.1%, p< 0.0001), emergency room (ER; 47.0% vs. 
15.4%, p< 0.0001), physician office (73.6% vs. 47.3%, p< 0.0001) and outpatient visits 
(98.9% vs. 71.6%, p< 0.0001). Higher health care resource utilizations translated to 
higher costs for post-menopausal fracture patients than for controls, including long-
term care ($9,191 vs. $7,212, p< 0.0001), physician office visit ($428 vs. $293, p< 0.0001) 
and total costs ($17,698 vs. $13,032, p< 0.0001). ConClusions: Post-menopausal 
women with fractures had significant health care resource utilization and expenses 
compared to those without fractures.
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evaluatIon of tHe PotentIal ImPaCt of drug-gene InteraCtIon rIsk 
(dgIr) on HealtH resourCe utIlIzatIon (Hru)
Bress A1, Unni S1, Biltaji E1, Sass RS2, Mamiya T2, Ye X1, Yu B1, Biskupiak JE1, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2Genelex, Inc, Seattle, WA, USA
objeCtives: To assess the relationship between DGIR and HRU in elderly patients 
to evaluate potential benefit from pharmacogenetic testing. Methods: A ret-
rospective cohort of patients age ≥ 65 years was identified through Inovalon’s 
MORE2® registry with continuous enrollment, taking ≥ 3 prescription medications 
(July 1, 2012 - March 31, 2013) and on ≥ 1 drug metabolized by a polymorphic drug 
metabolizing enzyme. Patients were stratified into zero, low, medium, and high 
DGIR groups via a diagnostic test (Genelex Youscript®). Counts of HRU during 9 
months follow-up post index-date (date of first claim for ≥ 1 drugs with pharma-
cogenetic implications) included all-cause hospitalizations, emergency-room and 
clinic visits. Poisson regression was used to test the association between DGIR and 
HRU counts. The model was adjusted for age, gender, race, Charlson Comorbidity 
Index (CCI) and number of known drug-drug interactions. Results: A total of 
252,184 patients were included and the mean age was 74 ± 6 and 60% were female. 
The median DGIR score was 8.7% [IQR 2.3%-44%]. There were 59,559 (23.6%) with 
a DGIR score of zero, 82,224 (32.6%) with low risk (0-20%), 33,439 (13.3%) with 
medium risk (20-40%), and 76,962 (30.5%) with high risk (> 40%). Regression analy-
sis revealed that the low and medium DGIR groups were associated with a 9% 
(95%CI 8.4 to 9.7%, p < 0.0001), and 8% (95%CI 7.7 to 9.2%, p < 0.0001) increase 
in the rate of HRU, compared to zero risk. The high DGIR group was associated 
with a 5% (95%CI 4.2 to 5.3%, p < 0.0001) decrease in HRU, compared to zero-
risk. ConClusions: Among elderly patients, low and medium DGIR groups were 
associated with increased rates of HRU. In contrast, high DGIR was associated with 
lower HRU rates. This may be explained by a time-dependent effect of changing 
DGIR as a result of medication changes over time.
